MRMuhammad Azhar Rosyidi

Muhammad Azhar Rosyidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Azhar Rosyidi has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability

    by Valerinna Yogibuana, Muhammad Azhar Rosyidi, Muhammad Reva Aditya

    Background: Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalization remain limited. Methods: This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication. Result: A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2.91, 95% CI 1.67–5.07; Model 2: OR 2.84, 95% CI 1.63–4.95; Model 3: OR 2.97, 95% CI 1.66–5.32; all p < 0.001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1.51–1.77). Therapy use: Beta Blocker (BB) (OR 0.54), MRA (OR 0.43), and ARNI (OR 0.19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0.73, 95% CI 0.68–0.78) and robust calibration (Hosmer Lemeshow p = 0.41. Conclusion: A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient. Keyword : Acute Heart Failure; Echocardiography; Left Heart Disease; Major Adverse Cardiovascular Events; Pulmonary Hypertension.

  • Prognostic implications of pulmonary hypertension in heart failure preserved and reduced ejection fraction

    by Muhammad Azhar Rosyidi, Valerinna Yogibuana

    Pulmonary hypertension (PH) attributable to left heart disease (PH associated with left heart disease, PH-LHD) is the most common type of PH. PH-LHD is an important indicator of elevated morbidity and mortality in individuals with heart failure, both heart failure with preserved and reduced ejection fraction despite receive adequate therapy. Literature was sourced from major scientific databases and studies relevant to symptoms, examinations, management, and prognostic implications of PH-LHD. Pathophysiologically, PH-LHD is a gradual process that begins with increased left-heart pressure (postcapillary component), which triggers a series of biological changes in the pulmonary vasculature (precapillary component). This process ultimately places an excessive burden on the right ventricle, resulting in right ventricular dysfunction and failure, which are the main determinants of prognosis. Symptoms of PH-LHD are usually characterized by disproportionate dyspnea that is not consistent with left ventricular ejection fraction and other comorbidities. Echocardiography can noninvasively assess the probability of pulmonary hypertension in heart failure patients. A definitive diagnosis of PH-LHD requires confirmation through right heart catheterization. The most important prognostic factors are not only determined by the degree of hemodynamic severity, but also depend heavily on the degree of right ventricular dysfunction and the status of right ventricle–pulmonary artery coupling. Management of PH-LHD is through optimization of basic Guideline-Directed Medical Therapy (GDMT) to reduce mortality and morbidity. Keyword : Heart Failure; Left Heart Disease; Pulmonary Hypertension.